Clinical Trial Update: Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a multi-agent regimen of fludarabine phosphate, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin hydrochloride in adu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Filgrastim-sndz (filgrastim-sndz)
• Fludarabine phosphate (Fludarabine phosphate)
• Gemtuzumab ozogamicin (gemtuzumab ozogamicin)
• Idarubicin hydrochloride (idarubicin hydrochloride)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 | Phase 2 | Status: RECRUITING